

| | | | |
|--------------------|-----------------------|-----------------|-------|
| POLICY NAME | Synagis (palivizumab) | POLICY # | 2325P |
|--------------------|-----------------------|-----------------|-------|

Criteria

Coverage Criteria for diagnosis of Congenital Airway Abnormality or Neuromuscular Condition

- ☐ 1.1 Documentation of nerves and muscular disorder or congenital abnormality that impairs the ability to cough up mucus from the upper lungs because of ineffective cough
- ☐ 1.2 Age 12 months or younger

Coverage Criteria for diagnosis of Congenital Heart Disease (CHD)

- ☐ 2.1 Documentation of CHD hemodynamically significant
- ☐ 2.2 Age 12 months or younger

Coverage Criteria for diagnosis of Chronic Lung Disease (CLD)

- ☐ 3.1 Age 24 months or younger
- ☐ 3.2 Documentation that patient has received medical treatment for CLD in the 6 months prior to RSV season (medical treatment may include oxygen, bronchodilators, diuretics, or chronic corticosteroids)

Coverage Criteria for diagnosis of Prematurity

- ☐ 4.1 Gestational age of 28 weeks 6 days
- ☐ 4.2 Chronological age at the start of RSV season of < 12 months

Exclusion Criteria – Any of the following prevents coverage

- ☐ 5.1 Patients who were already vaccinated against RSV with Beyfortus are not recommended to receive Synagis as well